HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.

AbstractAIMS:
A significant increase in congestive heart failure (CHF) was reported when the anti-ErbB2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (Dox). The aim of the present study was to investigate the role(s) of miRNAs in acute Dox-induced cardiotoxicity.
METHODS AND RESULTS:
Neuregulin-1-ErbB signalling is essential for maintaining adult cardiac function. We found a significant reduction in ErbB4 expression in the hearts of mice after Dox treatment. Because the proteasome pathway was only partially involved in the reduction of ErbB4 expression, we examined the involvement of microRNAs (miRs) in the reduction of ErbB4 expression. miR-146a was shown to be up-regulated by Dox in neonatal rat cardiac myocytes. Using a luciferase reporter assay and overexpression of miR-146a, we confirmed that miR-146a targets the ErbB4 3'UTR. After Dox treatment, overexpression of miR-146a, as well as that of siRNA against ErbB4, induced cell death in cardiomyocytes. Re-expression of ErbB4 in miR-146a-overexpressing cardiomyocytes ameliorated Dox-induced cell death. To examine the loss of miR-146a function, we constructed 'decoy' genes that had tandem complementary sequences for miR-146a in the 3'UTR of a luciferase gene. When miR-146a 'decoy' genes were introduced into cardiomyocytes, ErbB4 expression was up-regulated and Dox-induced cell death was reduced.
CONCLUSION:
These findings suggested that the up-regulation of miR-146a after Dox treatment is involved in acute Dox-induced cardiotoxicity by targeting ErbB4. Inhibition of both ErbB2 and ErbB4 signalling may be one of the reasons why those patients who receive concurrent therapy with Dox and trastuzumab suffer from CHF.
AuthorsTakahiro Horie, Koh Ono, Hitoo Nishi, Kazuya Nagao, Minako Kinoshita, Shin Watanabe, Yasuhide Kuwabara, Yasuhiro Nakashima, Rieko Takanabe-Mori, Eiichiro Nishi, Koji Hasegawa, Toru Kita, Takeshi Kimura
JournalCardiovascular research (Cardiovasc Res) Vol. 87 Issue 4 Pg. 656-64 (Sep 01 2010) ISSN: 1755-3245 [Electronic] England
PMID20495188 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3' Untranslated Regions
  • MIRN146 microRNA, rat
  • MicroRNAs
  • Mirn146 microRNA, mouse
  • Neuregulins
  • Doxorubicin
  • ERBB4 protein, human
  • ErbB Receptors
  • Erbb4 protein, mouse
  • Erbb4 protein, rat
  • Receptor, ErbB-4
  • Proteasome Endopeptidase Complex
Topics
  • 3' Untranslated Regions
  • Animals
  • Apoptosis
  • Cardiomyopathies (chemically induced, genetics, metabolism, pathology)
  • Cells, Cultured
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Doxorubicin (toxicity)
  • ErbB Receptors (genetics, metabolism)
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs (metabolism)
  • Mutation
  • Myocytes, Cardiac (drug effects, metabolism, pathology)
  • Neuregulins (metabolism)
  • Proteasome Endopeptidase Complex (metabolism)
  • RNA Interference
  • Rats
  • Receptor, ErbB-4
  • Signal Transduction
  • Time Factors
  • Transfection
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: